Search

Your search keyword '"Dalhoff K"' showing total 27 results
Start Over Author "Dalhoff K" Publisher georg thieme verlag stuttgart
27 results on '"Dalhoff K"'

6. Urine and Serum Concentrations of Inhaled and Oral Terbutaline.

Author

Elers, J., Hostrup, M., Pedersen, L., Henninge, J., Hemmersbach, P., Dalhoff, K., and Backer, V.

Subjects
DRUG therapy for asthma, NITRIC oxide analysis, ANALYSIS of variance, ASTHMA, CROSSOVER trials, ORAL drug administration, RESEARCH funding, SKIN tests, SPIROMETRY, STATISTICS, T-test (Statistics), U-statistics, DATA analysis, CASE-control method, TERBUTALINE, DATA analysis software, DESCRIPTIVE statistics, INHALATION administration
Abstract

We examined urine and serum concentrations after therapeutic use of single and repetitive doses of inhaled and supratherapeutic oral use of terbutaline. We compared the concentrations in 10 asthmatics and 10 healthy subjects in an open-label, cross-over study with 2 mg inhaled and 10 mg oral terbutaline on 2 study days. Further, 10 healthy subjects were administrated 1 mg inhaled terbutaline in 4 repetive doses with total 4 mg. Blood samples were collected at baseline and during 6 h after the first inhalations. Urine samples were collected at baseline and during 12 h after the first inhalations. Median (IQR) urine concentrations peaked in the period 0]4 h after inhalation with C max 472 (324) ng/mL in asthmatics and 661 (517) ng/mL in healthy subjects, and 4]8 h after oral use with C max 666 (877) ng/mL in asthmatic and 402 (663) ng/mL in healthy subjects. In conclusion we found no significant differences in urine and serum concentrations between asthmatic and healthy subjects. We compared urine and serum concentrations after therapeutic inhaled doses and supratherapeutic oral doses and observed significant statistical defenses in both groups but found it impossible to distinguish between therapeutic and prohibited use based on doping tests with urine and blood samples. [ABSTRACT FROM AUTHOR]

Published
2012
Full Text
View/download PDF

8. Urine Concentrations of Repetitive Doses of Inhaled Salbutamol.

Author

Elers, J., Pedersen, L., Henninge, J., Hemmersbach, P., Dalhoff, K., and Backer, V.

Subjects
AEROSOL therapy, ALBUTEROL, ANALYSIS of variance, ASTHMA, COMPUTER software, RESEARCH funding, SKIN tests, U-statistics, DATA analysis, CASE-control method
Abstract

We examined blood and urine concentrations of repetitive doses of inhaled salbutamol in relation to the existing cut-off value used in routine doping control. We compared the concentrations in asthmatics with regular use of beta2- agonists prior to study and healthy controls with no previous use of beta2-agonists. We enrolled 10 asthmatics and 10 controls in an open-label study in which subjects inhaled repetitive doses of 400 microgram salbutamol every second hour (total 1 600 microgram), which is the permitted daily dose by the World Anti-Doping Agency (WADA). Blood samples were collected at baseline, 30 min, 1, 2, 3, 4, and 6h after the first inhalations. Urine samples were collected at baseline, 0-4 h, 4-8h, and 8-12h after the first inhalations. Median urine concentrations peaked in the period 4-8 h after the first inhalations in the asthmatics and between 8-12h in controls and the median ranged from 268 to 611 ng×Ml1. No samples exceeded the WADA threshold value of 1 000 ng×mL1 when corrected for the urine specific gravity. When not corrected one sample exceeded the cut-off value with urine concentration of 1 082 ng×mL1. In conclusion we found no differences in blood and urine concentrations between asthmatic and healthy subjects. We found high variability in urine concentrations between subjects in both groups. The variability between subjects was still present after the samples were corrected for urine specific gravity. [ABSTRACT FROM AUTHOR]

Published
2011
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results